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1. Based on the initial presentation of macroscopic hematu-
ria, proteinuria, and renal failure following an episode of
pharyngitis with a typical time lag of 2 weeks, the differ-
ential diagnosis consists primarily of acute post-infectious
glomerulonephritis (PIGN), the first presentation of either
immune complex, or complement-mediated mem
branoproliferative nephritis (MPGN), or IgA nephropathy
(IgAN) triggered by an infection. Less likely, but not ex-
cluded, are ANCA vasculitis, lupus nephritis, anti-
glomerular basement (GBM) glomerulonephritis, and
toxicity-/medication-induced glomerulonephritis. The
young age and lack of sinusitis or pulmonary symptoms
make ANCA vasculitis less likely and there were neither
physical nor anamnestic signs of systemic lupus erythema-
tosus (SLE). Macroscopic hematuria and nephrotic protein-
uria are less consistent with a toxic cause of acute kidney
injury. Given the clinical course, the patient had suspected
rapidly progressive glomerulonephritis (RPGN).
2. Additional laboratory investigations should be aimed at pos-
sible causes of RPGN [1]. The few available studies on
pediatric RPGN report that it is caused in over 80% by a
form of immune-complex-mediated glomerulonephritis,
with MPGN, Henoch–Schönlein purpura (HSP)/IgA ne-
phropathy and PIGN as the most frequent underlying causes
[2–5]. Lupus nephritis, C3 glomerulonephritis (C3GN), and
ANCA vasculitis are more infrequent causes of pediatric
RPGN [2–5]. In our patient, additional serummeasurements
included anti-streptolysin titer (AST) and anti-DNAse B ti-
ter, mycoplasma, hepatitis B andC serology, ANA, anti-PR3
ANCA, anti-MPO ANCA, anti-GBM measurements, and a
full complement cascade for assessment of both the classical
and alternative pathways (C3, C4, C3d, AP50, CH50, C3
nephritic factor, C5b-9).
3. On the day after admission, the patient developed oliguria
and a steep rise in creatinine level, indicating a rapid pro-
gression of renal failure. Although therewas a high degree of
suspicion regarding PIGN, serum complement C3 and C4
levels and AST and anti-DNAse B titer were not yet avail-
able. Generally, a renal biopsy is not mandatory when PIGN
is suspected. However, certain features atypical of PIGN
should prompt a biopsy. These include RPGN, extra-renal
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manifestations, a patient’s age <2 years, persistent gross he-
maturia, hypertension or nephritic syndrome, and
hypocomplementemia lasting >6 weeks [6]. In view of the
rapid course of the acute kidney injury in our patient, a renal
biopsy was planned for the next available appointment,
which was the next day.
4. There is little evidence regarding the treatment of RPGN in
children and existing guidelines are based on studies in
adults, in whom the underlying cause of the glomerulone-
phritis is usually different. For instance, adults have a higher
likelihood of ANCA vasculitis [1]. Nevertheless, there is a
general consensus that methylprednisolone pulse therapy
with or without cyclophosphamide, is the first therapeutic
regimen in RPGN [2–5, 7]. In our patient, we refrained from
immunosuppressive treatment before a biopsy had been ob-
tained. At the time, there was a high degree of suspicion
regarding either PIGN or MPGN (immune complex- or
complement-mediated). Methylprednisolone pulse therapy
was not started, as there is a lack of evidence for a beneficial
effect of immunosuppressive therapy in PIGN [7, 8]. Also,
we feared that high doses of steroids might influence the
renal biopsy. BBlind^ administration of eculizumab was also
considered but rejected for lack of a diagnosis and in view of
its high costs. Supportive treatment consisting of fluid re-
striction, diuretics, and antibiotics was continued, awaiting
the serum complement results.
5. In our patient, the renal biopsy and serum complement re-
sults imposed a diagnostic dilemma, which is described be-
low. On the third day of admission, a Monday, serum com-
plementmeasurements were found to be normal (C3: 1.15 g/
l, reference value 0.9–1.8 g/l; C4: 0.43 g/l; reference value
0.1–0.49 g/l). AST and anti-DNAse B titer were not yet
available. Creatinine levels continued to rise to 640 μmol/l
(7.2 mg/dl) and oliguria persisted. Because of the clinical
picture of RPGN, together with the absence of
hypocomplementemia characteristic of PIGN, this initial di-
agnosis was considered less likely, as was a complement-
mediated MPGN. A renal biopsy was performed on the
same day, combined with the placement of a central venous
line for hemodialysis. Methylprednisolone pulse therapy
(three daily pulses of 500 mg/m2 body surface area) was
started immediately after the renal biopsy. Histopa thological
evaluation of the renal biopsy showed crescentic glomerulo-
nephritis in all 25 glomeruli (100% crescents), together with
some endocapillary hypercellularity due to granulocyte infil-
tration. All crescents were cellular, with no signs of chronic-
ity (Fig. 1a, b). There was also mild interstitial edema and
tubules were dilated and filled with erythrocytes and
granulocytes (Fig. 1c). Immunofluorescence was negative
for IgG (Fig. 1d), IgM, IgA, kappa, lambda, and C1q, but
revealed coarse granular C3c deposits along the capillary
walls (2+), the so-called Bstarry-sky^ pattern (Fig. 1e). C4d
staining was negative and C5b9 staining was similar to C3c.
Electron microscopy showed several (subepithelial) humps
(Fig. 1f) and tiny subendothelial electron dense deposits.
Intramembranous garland-like electron dense deposits com-
patiblewith dense deposit disease (DDD)were not observed.
These findings could be associated with both C3GN and
severe PIGN.
Intermittent hemodialysis was started on the fourth day
after admission. AST and anti-DNAse B titer were still not
available, nor were the bacterial and viral serology investi-
gations. As renal biopsy findings were consistent with both
PIGN and C3GN, a diagnosis of C3GN due to an intrinsic
complement defect, triggered by an infection, could not be
ruled out, despite the normal complement C3 level. In view
of the severity of the clinical course, the biopsy findings with
100% crescents and recent publications reporting promising
results of the complement inhibitor eculizumab for C3GN
[9–11], a single dose of eculizumab (375 mg/m2 body sur-
face area) was administered intravenously awaiting further
results. Complement cascade diagnostic investigations had
been undertaken before eculizumab administration to pre-
vent difficulties in interpretation of the results. Over the fol-
lowing days, intermittent hemodialysis was continued. The
AST returned highly positive (1,600 U/ml), as did the anti-
DNAse B titer (>1,600 U/ml), indicative of a recent strepto-
coccal infection. Mycoplasma and hepatitis B/C serology
were negative. Complement cascade analysis showed mild
complement alternative pathway route activation (114%; ref-
erence value: 40–110%), with elevated alternative comple-
ment byproduct C3d (4.8%; reference value: 0.5–3.1%) and
normal C5b-9 (<1,2 AE/ml; reference value:<4 AE/ml). C3
nephritic factor was negative, as were ANA, ANCA, and
anti-GBM antibodies. From the sixth day after admission
onward, renal function improved rapidly and hemodialysis
treatment was discontinued. The patient was discharged
11 days after admission, with a serum creatinine level of
106 μmol/l (1.2 mg/dl) and without medication. At last fol-
low-up, 2 months after presentation, renal function had
completely recovered (creatinine 42 μmol/l (0.5 mg/dl),
eGFR according to Schwartz was 116 ml/min/1.73 m2),
and proteinuria levels had declined significantly (protein to
creatinine ratio: 55.2 mg/mmol Cr). This clinical course of
rapid improvement favors the diagnosis of PIGN with
RPGN presentation.
Discussion
Post-infectious glomerulonephritis is an immunologically medi-
ated glomerular injury triggered by an infection. In children,
>95% of cases are caused by streptococcal infections.
Poststreptococcal glomerulonephritis (PSGN), induced by
Bnephritogenic^ group A streptococcal pharyngitis or skin
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infections, is a classic example of PIGNwith diffuse proliferative
and exudative glomerular histology, dominant C3 staining, some
IgG deposition, and subepithelial hump-like deposits [6, 12].
Typical PSGN usually presents with acute nephritic syndrome
of variable severity, transient serum C3 hypocomplementemia
(for 4–8 weeks) and generally resolves without complications
within a short period [6, 8, 13]. Most children and young adults
with PIGN have an excellent prognosis and >90% regain normal
renal function at short-term follow-up. Poor prognostic factors
include nephrotic syndrome, acute kidney injury requiring dial-
ysis, large and fibrous crescents, and signs of chronicity in the
renal biopsy [2, 6, 8, 13, 14]. The few available long-term follow-
up studies suggest that PSGN might not be entirely a benign
disease, with persistent non-nephrotic proteinuria or hematuria
in some children and development of ESRD in <1% of patients
[6, 14, 15]. Studies regarding pediatric RPGN or crescentic glo-
merulonephritis, report PIGN as the underlying cause in 7–50%
of cases, with the highest incidence of PIGN in developing
countries [2–5]. One study of 67 pediatric RPGN patients in
Thailand reported progression to ESRD in 35% of patients at a
median follow-up of 1 year [5]. In the more severely affected
patients, those with >50% crescents on biopsy and all treated
with methylprednisolone pulse therapy, 11 out of 19 patients
(57%) proceeded to ESRD. In this study, RPGN was ascribed
to PIGN in 50% of cases, and 16.7% of ESRD patients had
PIGN as an underlying etiology. The study concluded that pa-
tients with RPGN from PIGN had a better renal outcome than
patients with RPGN of other etiologies, with the worst prognosis
for immune-complex-mediated glomerulonephritis and lupus ne-
phritis (54.1% and 29.2% of ESRD patients respectively) [5].
Other pediatric studies report incidences of CKD/ESRD of 0–
31% for PIGNpresentingwithRPGN,with the highest incidence
of ESRD in developing countries [2–4, 7]. One explanation for
this higher prevalence of ESRD in developing countries may be
delayed referral, as signs of chronicity were often reported in the
biopsies [3, 5].
Fig. 1 Light microscopy, immunofluorescence, and electron microscopy
findings in the renal biopsy. a Light microscopy shows three crescentic
glomeruli (100% crescents in the whole biopsy), together with some
interstitial edema and dilated tubules (silver staining, ×10). No signs of
chronicity. b Higher magnification of a crescentic glomerulus with some
endocapillary hypercellularity due to granulocyte infiltration (silver
staining, ×20). c Light microcopy shows dilated tubules filled with
erythrocytes and granulocytes (silver staining, ×20). d Negative
immunofluorescent staining of a glomerulus for IgG (×20). e C3c
immunofluorescent staining showing coarse granular deposits along the
capillary walls (2+), the so-called Bstarry-sky^ pattern (×20). f Electron
microscopy showing large sub-epithelial electron-dense deposits
(Bhumps^) marked with asterisks associated with effacement of the
podocytes
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In our patient, the high AST and anti-DNAse B titers com-
bined with the renal biopsy findings and favorable outcome
despite the presence of 100% crescents on biopsy, strongly
favor PIGN as the underlying cause of RPGN. The finding
of (repeatedly) normal complement C3 levels in our patient is
unusual, but has been reported previously, with incidences
ranging from 5 to 36% in patients with PIGN requiring a renal
biopsy [7, 13, 16]. In the study by Wong et al., normal com-
plement C3 levels were reported in 9 out of 25 patients with
severe PIGN, 4 of whom required hemodialysis. One of these
patients had 100% crescents in the renal biopsy and similar to
the course of our patient, this patient had a favorable outcome
with a creatinine level of 87 μmol/l (0.9 mg/dl) at the age of
11.7 years after almost 8 years of follow-up [7].
Another remarkable biopsy finding in our patient was the
dominance of C3 staining on immunofluorescence and a com-
plete lack of IgG deposition. This finding can be associated
with a late biopsy during the course of PIGN, as IgG deposi-
tions may decline during the course of the disease [14, 15].
Generally, dominant C3 staining is more consistent with C3
glomerulopathy (C3G) [9, 17, 18]. C3G is a relatively new
term describing a spectrum of glomerular patterns of injury
that is associated with complement alternative pathway dys-
regulation with predominant C3 deposition and absent or neg-
ligible immunoglobulin staining in renal biopsies. C3G can be
histologically divided into DDD and C3GN, depending on the
pattern and location of the deposits. Humps can be found in
both DDD and C3GN [9, 18]. More than 90% of patients with
C3G show depressed serum complement C3 levels, but levels
may vary during the course of the disease [9, 18], and genetic
mutations in complement alternative pathway regulation are
increasingly reported [18, 19]. In our patient, the immunoflu-
orescence and electron microscopy findings (coarse and gran-
ular C3 pattern, IgG negative, subepithelial deposits (humps),
a few nonlinear subendothelial electron-dense deposits) were
compatible with both PIGN and C3GN, making it difficult to
establish the appropriate therapeutic approach. Therefore,
considering the severe clinical presentation, a therapy regimen
based on both diagnoses was chosen, despite the lack of evi-
dence for beneficial effects of eculizumab on C3G [19].
Interestingly, a recent study retrospectively describes and re-
defines biopsy findings in 33 pediatric patients initially diag-
nosed with PIGN and hypothesizes that PIGN and C3Gmight
define a disease spectrum [17]. The authors re-define PIGN
and C3G subgroups based on C3 and IgG staining patterns
and the presence and location of electron-dense deposits as
follows: a PIGN group (n = 25) with subepithelial deposits
and positive C3 staining with IgG staining present (group A)
or absent (group B), a C3G group (n = 8) based on dominant
C3 staining without subepithelial deposits regardless of IgG
staining (subgroup C) or dominant C3 staining with
intramembranous dense deposits and absent IgG staining
(subgroup D). The newly defined PIGN patients had a more
favorable clinical outcome (85% complete recovery), com-
pared with the newly defined C3G group (66% and 25% com-
plete recovery for groups C and D respectively). The authors
conclude that patients with C3G tended to have a milder and
more insidious clinical presentation, but a worse prognosis. It
is interesting to note that in the reported study, only 1 of the 23
PIGN patients with detailed clinical reports had a clinical pro-
file similar to that of our patient (i.e. dominant C3, absent IgG,
humps, and an absence of C3 hypocomplementemia) [17].
The above underscores the difficulty in interpreting the clini-
copathological data in our patient. During follow-up, our pa-
tient showed normalization of the initially raised C3d levels
and her serum C3 levels remained normal. Therefore, the di-
agnosis of C3GN was rejected and genetic screening for com-
plement alternative pathway mutations (i.e., complement fac-
tor H and related proteins, complement factor I mutations) was
not performed. It should be recognized that C3G may present
following an infectious episode, often a streptococcal infec-
tion, and that subepithelial deposits may also be a feature of
C3GN. Therefore, the presence of any atypical clinical or
histological features in a case of apparent PIGN should raise
the suspicion of C3GN and warrant alternative complement
pathway investigations, including mutational screening.
In summary, our case shows that PIGN can have a favor-
able course, despite a presentation as RPGN with massive
crescent formation on biopsy and acute kidney injury requir-
ing temporary dialysis. Involvement of the alternative com-
plement pathway route, as observed on renal biopsy, can occur
in the absence of a decreased plasma C3 level. Whether the
combined administration of methylprednisolone and
eculizumab positively influenced the course of disease might
be a subject for further studies.
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